This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Hedge Fund Favorites to Buy This Fall

Johnson & Johnson

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

You don't get anymore blue-chip than Johnson & Johnson (JNJ - Get Report). The $189 billion health care firm may be best known for consumer products like Band-Aid brand bandages and Tylenol, but the firm also owns huge medical device and pharmaceutical units too.

Hedge funds picked up shares of JNJ en masse in the second quarter, piling on 18.97 million shares to hike their holdings of the stock up to $4.53 billion. (Johnson & Johnson is one of the top holdings of Renaissance Technologies.)

>>5 Blue-Chip Stocks to Buy to Beat the S&P

Johnson & Johnson is focused on staying a well-diversified healthcare company. While pharma ballooned to nearly 40% of the firm's sales in recent years, that number should make its way down below 30% again in the near-term, thanks to the same patent losses challenging the rest of the industry and major acquisitions in the medical device arena. Healthcare is a recession-resistant business that's only looking stronger in the wake of healthcare reform. Regardless of the politics involved, more folks able to pay for JNJ's drugs and medical devices will ultimately boost the firm's bottom line.

Already, JNJ has mountains of cash. At last count, the firm's coffers stood $17 billion deep, offsetting a debt position of just over half that. That abundance of dry powders should continue to provide growth-by-acquisition opportunities for the firm (even after the huge Synthes deal), and keep its dividend payout big.

Investors looking for a defensive addition to their portfolio could do worse than copying hedge funds on the JNJ trade.
4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
AMZN $548.90 -0.23%
JNJ $95.45 -0.56%
KMI $31.48 -2.51%
NWSA $13.91 0.00%
PG $74.11 -0.30%


Chart of I:DJI
DOW 17,081.89 -49.97 -0.29%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,796.6090 -42.0340 -0.87%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs